BMT and Leukemia Program, Washington University School of Medicine, St. Louis, Missouri.
Siteman Cancer Center, Biostatistics Shared Resource, Washington University School of Medicine, St. Louis, Missouri.
Biol Blood Marrow Transplant. 2018 Oct;24(10):2047-2055. doi: 10.1016/j.bbmt.2018.05.024. Epub 2018 May 24.
T cell replete HLA-haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide was originally described using a reduced-intensity conditioning (RIC) regimen. Given that myeloablative conditioning (MAC) is more effective at preventing disease relapse, we compared outcomes of patients receiving MAC and RIC regimens. We evaluated overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-versus-host disease (GVHD) of 148 patients that underwent haplo-HCT with either MAC (n = 61) or RIC (n = 87). Propensity score adjustment (PSA) was used to balance baseline characteristics between groups and more effectively compare outcomes based on conditioning intensity. After the PSA analysis, relapse was significantly decreased with MAC (hazard ratio [HR], .47; 95% confidence interval [CI], .31 to .70), but was associated with higher NRM (HR, 1.74; 95% CI, 1.13 to 2.67). OS and DFS were not significantly different between groups (HRs for MAC versus RIC were .87 [95% CI, .64 to 1.18] and .90 [95% CI, .68 to 1.18] for OS and DFS, respectively). Rates of acute and chronic GVHD were not significantly different between groups. This analysis suggests that both MAC and RIC regimens are effective in haplo-HCT and that MAC regimens may result in less relapse in selected patients. These results need to be verified in a larger registry study.
T 细胞富含 HLA 单倍体相合造血细胞移植(haplo-HCT)联合移植后环磷酰胺最初是使用减强度预处理(RIC)方案描述的。鉴于清髓性预处理(MAC)在预防疾病复发方面更有效,我们比较了接受 MAC 和 RIC 方案的患者的结局。我们评估了 148 例接受 haplo-HCT 的患者的总生存率(OS)、无病生存率(DFS)、复发、非复发死亡率(NRM)和移植物抗宿主病(GVHD),这些患者接受 MAC(n=61)或 RIC(n=87)预处理。采用倾向评分调整(PSA)来平衡组间的基线特征,并根据预处理强度更有效地比较结局。PSA 分析后,MAC 显著降低了复发率(危险比 [HR],.47;95%置信区间 [CI],.31 至.70),但与较高的 NRM 相关(HR,1.74;95% CI,1.13 至 2.67)。OS 和 DFS 在两组之间无显著差异(MAC 与 RIC 的 HR 分别为 OS 的.87 [95% CI,.64 至 1.18]和 DFS 的.90 [95% CI,.68 至 1.18])。两组间急性和慢性 GVHD 的发生率无显著差异。这项分析表明,MAC 和 RIC 方案在 haplo-HCT 中均有效,并且 MAC 方案可能使选定患者的复发率降低。这些结果需要在更大的登记研究中得到验证。